King Abdullah Medical Complex Jeddah and Maternity and Children's Specialist Hospital optimize operations with InterSystems TrakCare MEUI Upgrade
Successful digital health transformation needs comprehensive user adoption and the InterSystems TrakCare mobile enabled user interface (MEUI) is a key component to scaling adoption by extending device and care-setting choice with intuitive ease of use.
Jeddah, Saudi Arabia: InterSystems, a creative data technology provider dedicated to helping customers solve the most critical scalability, interoperability, and speed problems, are pleased to share that King Abdullah Medical Complex Jeddah (KAMCJ) and Maternity and Children's Specialist Hospital (MCSH) have upgraded their Electronic Medical Record (EMR) to the latest version of InterSystems TrakCare® unified health information system.
KAMCJ is a 500-bed hospital complex under the Ministry of Health that provides elective medical and surgical services combined with a state-of-the-art laboratory, trauma center and outpatient clinics serving North Jeddah. MCSH is a 300-bed hospital that provide healthcare services for women and all diseases related to women's health by qualified, specialized, and highly professional doctors using the latest equipment and technologies through outpatient clinics, in addition to receiving all emergency cases in the emergency department.
The EMR upgrade is a major milestone in both facilities' digital health transformation journey — that enhances patient care and streamlines their operations. Without comprehensive user adoption digital health transformations fail. The latest, easy-to-use TrakCare interface adds to the user's choice of device and care-setting to further support the delivery of the highest levels of patient-focused, quality, and safety outcomes. At the same time, the hospitals unlocked new value from their EMRs by adopting unified modules for the intensive care unit, anesthesia, and maternity. Using a unified EMR ensures information captured once is available immediately to cross-departmental authorized users to avoid data silos. They also upgraded and added blood bank services to their laboratory information management system (LIMS) that uses InterSystems TrakCare Laboratory Enterprise®.
The upgrade was smooth and successful because KAMCJ and MSCH multi-disciplined teams engaged stakeholders, communicated the leadership vision for the next generation of care services, and professionally executed a user training program supported by a close partnership with InterSystems implementation team.
'Our success is driven by continuous growth and collaboration at all levels,' said Maha Hetaimish, Health Application Manager, King Abdullah Medical Complex Jeddah. 'We are proud of this achievement, as it directly contributes to the well-being of our patients, ensuring that we make informed decisions to provide the best care during their most critical moments. True success is the result of teamwork, commitment, and a shared vision. We are proud of this milestone, as it allows us to enhance the care we provide and ensure we make the right decisions for our patients when they need us most.'
'This upgrade is a key milestone for both KAMCJ and MCSH in their journey toward digital excellence. By embracing InterSystems' advanced technologies, they are not only improving operational efficiencies but also enhancing patient care and supporting their ongoing commitment to healthcare innovation,' said Ali Abi Raad, Managing Director, Middle East, India, and South Africa, InterSystems. Ali emphasized that, 'This joint success reflects KAMCJ's, MCSH's, InterSystems', and the leaders of the Jeddah Second Health Cluster's shared commitment to collaboration and innovation in driving healthcare excellence.'
Users access TrakCare from popular web-browsers from any secure device anytime and anywhere. The Mobile Enabled User Interface (MEUI) extends the accessibility and convenience of using the EMR with intuitive screen designs for mobile devices. Mobile device use gives users more options for capturing patient observations and treatment updates, which helps them make more informed and timely decisions while spending more time with patients.
The upgrade included new integrations to third-party computing solutions along with interoperability to the National Platform for Health and Insurance Exchange Services (NPHIES). InterSystems was one of the first multinational digital health companies certified as NPHIES compliant for insurance services in Saudi Arabia. NPHIES is a unified electronic services platform launched by the Cooperative Health Insurance Council (CCHI) and the National Center for Health Information (NHIC) and led by the SEHATI company with the aim to transform the health care sector in the Kingdom of Saudi Arabia by using the latest technologies to enhance the level and quality of health services in line with the Kingdom of Saudi Arabia's Vision 2030.
About King Abdullah Medical Complex Jeddah
The King Abdullah Medical Complex – Jeddah (KAMCJ) is a 500-bed hospital complex under the Ministry of Health providing elective medical and surgical services combined with a state-of-the-art laboratory, trauma center and outpatient clinics serving North Jeddah. KAMCJ is organized in accordance with the principles of multi-disciplinary team working and flexibility to ensure the highest standards of patient care and safety.
About Maternity and Children's Specialist Hospital
The Maternity and Children's Specialist Hospital provide health care services for women and all diseases related to women's health by qualified, specialized and highly professional doctors using the latest equipment and technologies through outpatient clinics, in addition to receiving all emergency cases in the emergency department around the clock.
About InterSystems
InterSystems, a creative data technology provider, delivers a unified foundation for next-generation applications for healthcare, finance, manufacturing, and supply chain. Our cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe to unlock the power of data and allow people to perceive data in imaginative ways. Established in 1978, InterSystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. Privately held and headquartered in Cambridge, Massachusetts, InterSystems has 39 offices in 28 countries worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
4 days ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
Al Etihad
03-06-2025
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
Arabian Post
21-05-2025
- Arabian Post
Uni-Bio Science Group Receives NMPA Approval for 金因康® (Diquafosol Sodium Eye Drops), Advancing Dry Eye Syndrome Treatment in China
HONG KONG SAR – EQS Newswire – 21 May 2025 – Uni-Bio Science Group Limited (the 'Company', together with its subsidiaries, the 'Group') proudly announces that its new ophthalmology product, 金因康(Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字H20254149]. This milestone strengthens the Group's portfolio in ophthalmology, addressing the growing demand for innovative treatments in China's dry eye syndrome market, which affects an estimated 360 million individuals. As the Group's second ophthalmology drug following GeneSoft®, 金因康® addresses the underlying causes of dry eye syndrome by activating P2Y2 receptors to stimulate tear fluid and mucin secretion. It offers: Improved tear layer normalization and corneal epithelial repair. Treatment for patients with dry eye accompanied by abnormal tear-associated corneal epithelial defects. A next-generation option for more effective and patient-friendly care. China's dry eye syndrome market is projected to surpass RMB 42 billion by 2030, growing at a CAGR of 28.4%, driven by increased screen time and evolving lifestyles. 金因康® is well-positioned to capture this growing demand with its proven efficacy and safety, widely recognized since the originator launched in Japan in 2010. ADVERTISEMENT To ensure rapid market penetration, the Group has expanded its sales force and integrated resources across hospitals, pharmacies, and e-commerce platforms. Strategic partnerships with API suppliers have secured high-quality raw materials at competitive costs, further enhancing 金因康®'s affordability and market competitiveness. Looking ahead, Uni-Bio Science Group will continue to focus on clinical needs and invest in R&D to expand its ophthalmic drug pipeline. With over 20 years of technological expertise, the Group is committed to delivering high-quality medical solutions, raising the standards of ophthalmic care, and solidifying its leadership in China's growing ophthalmology market. Hashtag: #Uni-BioScience The issuer is solely responsible for the content of this announcement. About Uni-Bio Science Group Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology. Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690. About 金因康® Diquafosol Sodium Eye Drops are a medication for treating dry eye disease and are suitable for patients diagnosed with dry eye accompanied by abnormal tear-associated corneal epithelial defects. Diquafosol Sodium represents the next generation of dry eye medication, offering cutting-edge therapy through its novel mechanism as a P2Y2 receptor agonist, stimulating tear and mucin secretion. This addresses the underlying causes of dry eye syndrome, normalizing the tear layer and improving corneal epithelial damage.
